Safety of NOAC instead of aspirin in ACS patients
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
Presented at ACC.17 by Magnus E OhmanNews - Mar. 18, 2017
- The median duration of treatment with blinded study drug was 291 days (IQR: 239–354) and the median duration of follow-up was 326 days (IQR: 284–383).
- Premature treatment discontinuation occurred in 11% of patients treated with rivaroxaban vs. 13% of patients treated with aspirin. Early discontinuation of P2Y12 inhibitor therapy was 4.4% in the overall population.
- 49% of patients presented with STEMI, 40% with NSTEMI, and 11% with unstable angina. 87% of patients were treated with PCI for their index ACS before randomisation.
- The primary endpoint of TIMI non-CABG clinically significant bleeding occurred in 5% of patients on rivaroxaban and 5% of patients on aspirin (HR: 1.09; 95% CI: 0.80–1.50; P=0.5840). The most common type of bleeding was TIMI bleeding requiring medical attention (4% in the rivaroxaban group and 4% in the aspirin group), with a low frequency of severe or major bleeding events using TIMI bleeding definitions.
- Using the ISTH definition for major bleeding, a higher rate of bleeding was noted with rivaroxaban compared with aspirin (2% vs. 1%; P=0.0420), but there were no differences using GUSTO or BARC bleeding definitions, regardless of severity.
- The frequency of the composite ischaemic endpoint of CV death, MI, stroke, or definite stent thrombosis was 5% in both groups (HR: 1.06; 95% CI: 0.77–1.46; P=0.7316).
A safety study of rivaroxaban versus aspirin, on top of P2Y12 therapy in ACS patients, showed that this dual antithrombotic regimen had a similar risk of clinically significant bleeding. These findings suggest that substituting aspirin with low-dose rivaroxaban is a safe therapeutic option in this setting.
Our coverage of ACC.17 is based on the information provided during the congress.